Verdict: Hoechst Pakistan delivered a genuinely stronger operating half, but the headline profit surge needs to be separated into two pieces. The underlying business improved as gross margin expanded sharply on production and procurement efficiencies and better product mix, while domestic sales grew despite weaker Afghanistan revenue. On top of that core improvement, a Rs670 million one-off gain from settling the Sindh infrastructure cess dispute lifted other income and magnified reported profit. Consolidated H1 profit after tax rose 63.2% to Rs2.191 billion. Q2 was even stronger on the face of the accounts, with PAT up 87.4%, but the SIDC accounting gain sits inside that quarter. Cash conversion was still positive, though operating cash flow fell year on year because tax payments were much higher and the working-capital release was smaller.
Results at a glance
- Company Name: Hoechst Pakistan Limited
- Ticker: HPL
- Reporting period: six months ended June 30, 2026, with separate analysis of the three months ended June 30, 2026.
- Reporting basis: the main analysis uses the unaudited consolidated statements of Hoechst Pakistan Limited, H-Pack Wellness (Private) Limited and Hoechst Pack Trading FZCO. The statutory auditor performed a limited-scope review only on the cumulative six-month unconsolidated statements; the standalone Q2 figures were not reviewed. The consolidated interim statements are unaudited.
- H1 consolidated revenue rose 2.5% to Rs16.704 billion. Gross profit increased 17.6% to Rs6.611 billion and gross margin expanded to 39.6% from 34.5%.
- H1 consolidated operating profit increased 56.3% to Rs3.757 billion and profit after tax rose 63.2% to Rs2.191 billion. EPS was Rs227.20 versus Rs139.25.
- Q2 consolidated revenue increased 3.3% to Rs9.005 billion, gross profit rose 24.0%, operating profit climbed 89.2%, and profit after tax rose 87.4% to Rs1.480 billion.
- The Board declared an interim cash dividend of Rs80 per share, amounting to about Rs771.6 million.
AlphaGen model outputs
The following are AlphaGen model outputs, not company-reported figures:
- Alpha QoQ Score: 94.99
- TTM Performance Score: 94.99
- 3Y Business Perf Score: 96.49
- Sector Leadership Score: 68.61
What improved
The most important recurring improvement was gross margin. Consolidated H1 revenue grew only 2.5%, yet cost of sales declined 5.4%, allowing gross profit to rise 17.6%. Gross margin increased by roughly 5.1 percentage points to 39.6%. In Q2 alone, the margin reached 40.5% compared with 33.7% a year earlier. Management’s standalone review attributes the H1 margin improvement to efficiencies in production and procurement and a better sales mix across multiple product categories. That explanation is economically consistent with the accounts: the business generated substantially more gross profit from only modest top-line growth.
Domestic demand also looked better than the headline revenue growth suggests. The group’s Pakistan revenue rose 6.2% to Rs16.493 billion in H1, while Afghanistan revenue fell 72.5% to Rs211.5 million. The revenue note also shows no gross export sales in Q2 versus Rs515.5 million in Q2 2025. That export contraction diluted the consolidated growth rate. In other words, the weak part of the sales bridge was geography rather than evidence of a broad collapse in the local franchise.
Operating leverage before exceptional income was also positive. Reported H1 operating profit rose 56.3% to Rs3.757 billion, but Rs670.5 million of that reflects the SIDC settlement and remeasurement gain recorded in other income. A simple analytical subtraction of that disclosed gain—before tax and without treating it as a company-defined adjusted metric—leaves roughly Rs3.086 billion of operating profit, still about 28% above the prior-year H1 figure. The core improvement therefore does not disappear when the one-off is removed; it simply becomes much less dramatic than the reported headline.
What weakened / needs attention
Commercial spending rose faster than revenue. Consolidated distribution and marketing costs increased 19.4% in H1 to Rs2.719 billion and 23.5% in Q2 to Rs1.449 billion. Management says promotional activities aligned with business requirements were the main reason the standalone distribution-and-marketing ratio rose to 16% of sales from 14%. Administrative expense increased a more moderate 8.4% in H1. The margin story is therefore not simply lower manufacturing cost: part of the gross-profit gain was reinvested behind the portfolio through selling and promotion.
Finance cost was flat for H1 at about Rs58 million, but Q2 finance cost almost doubled to Rs33 million from Rs16.7 million. The absolute burden remains small relative to operating profit, and the notes indicate the company had no running-finance mark-up in H1 2026, but the increase is worth watching because lease liabilities and the SIDC payment obligation now sit on the balance sheet. The SIDC liability also carries future unwinding finance cost as its present value accretes.
The SIDC gain: economically real, but not recurring earnings
The biggest earnings-quality adjustment is the Sindh Development and Maintenance of Infrastructure Cess settlement. The 2026 amendment to the provincial law introduced a formal settlement framework with installment payments and withdrawal of litigation. Hoechst entered a settlement agreement with the Government of Sindh on April 10, 2026. Under that agreement, the company recognized a Rs313.2 million reversal of previously provided SIDC liability and a Rs357.2 million gain from remeasuring the remaining liability to present value. Together, those items added about Rs670.5 million to other income.
This matters because consolidated other income jumped from Rs108 million to Rs864 million in H1 and from Rs63.9 million to Rs776.8 million in Q2. The settlement is not a recurring pharmaceutical earning stream, so it should not be projected forward. At June 30 the group carried Rs515.3 million of SIDC liability, split between Rs363.8 million non-current and Rs151.6 million current. The accounting gain improves reported 2026 earnings, while future cash payments and present-value unwinding move in the opposite direction.
Cash flow was weaker than the profit line
Higher accounting profit did not translate into higher operating cash flow. Consolidated cash generated from operations fell 10.8% to Rs5.102 billion, and net cash from operating activities declined 27.9% to Rs3.639 billion. The main reasons are visible in the cash-flow statement. H1 2026 benefited from a Rs1.127 billion inventory release and Rs303 million reduction in trade debts, but the prior-year period had an even larger working-capital release. More importantly, income tax paid nearly doubled to Rs1.154 billion from Rs587 million.
Cash generation was still healthy enough to fund significant capital allocation. Capital expenditure fell to Rs532 million from Rs1.188 billion, while dividends paid rose 73% to Rs1.826 billion. Net investing outflow was Rs1.677 billion and financing outflow Rs1.858 billion. Ending consolidated cash and cash equivalents were Rs291 million, broadly similar to the Rs297 million comparative balance. The key distinction is that H1 earnings quality was mixed: underlying operations generated substantial cash, but the year-on-year cash-flow trend was weaker than the income-statement trend.
Balance sheet and working capital
The consolidated balance sheet remained liquid. Current assets were Rs11.123 billion against current liabilities of Rs6.201 billion, implying a current ratio of about 1.79 times versus roughly 1.71 times at December 2025. Inventory declined 14.3% to Rs5.678 billion and trade receivables fell 37.3% to Rs501 million. Short-term investments more than doubled to Rs2.648 billion, while cash and bank balances increased to Rs291 million. Equity rose 4.4% to Rs8.552 billion.
The liability mix changed rather than showing conventional balance-sheet stress. Lease liabilities increased, and the new SIDC settlement created both current and non-current obligations. Trade and other payables eased slightly from year-end. There is no evidence in the interim balance sheet of a large bank-debt build-up. The bigger next-cycle question is whether lower inventory and receivables represent durable working-capital discipline or simply timing that will reverse as sales and imports normalize.
Subsidiaries and strategic development
The parent company remains overwhelmingly responsible for group earnings. H-Pack Wellness, the local wellness and nutraceutical subsidiary, generated H1 revenue of Rs35 million, gross profit of Rs23 million and PAT of Rs11 million. Hoechst Pack Trading FZCO, the Dubai subsidiary incorporated in November 2025, had not yet generated revenue in H1 2026 and incurred about Rs15.3 million of setup and office-running cost while establishing supply-chain arrangements. The parent invested Rs68.9 million in the UAE entity during the period.
That explains why consolidated profit after tax of Rs2.191 billion was slightly below the parent company’s Rs2.196 billion standalone PAT despite the local subsidiary being profitable. The UAE platform is therefore a cost center at this stage, not an earnings contributor. Its progress is worth following because the group’s Afghanistan revenue fell sharply, and management is simultaneously building a new regional trading and distribution capability.
What changed versus the historical pattern
The H1 margin improvement extends a multi-year recovery rather than appearing from nowhere. Hoechst’s audited 2025 annual report shows revenue increasing from Rs18.560 billion in 2022 to Rs30.929 billion in 2025, while gross margin rose from 26% to 37%. PAT moved from Rs167 million in 2022 to Rs2.910 billion in 2025. H1 2026 pushes the gross-margin trend further, but the pace of reported profit growth is temporarily exaggerated by the SIDC gain. The more durable evidence is the continued spread between revenue growth and gross-profit growth.
Peer evidence also argues against treating the entire result as a generic pharmaceutical-sector windfall. Abbott Pakistan’s official Q2 2026 result showed sales growth of about 6.6% and PAT growth of about 13.2% year on year. Hoechst’s 3.3% Q2 sales growth was slower, while its reported PAT growth was far larger because of company-specific margin expansion and the SIDC accounting gain. DRAP continues to maintain a public pharmaceutical product price system, confirming that regulatory pricing remains an operating variable for the sector. However, Hoechst’s H1 management commentary attributes its gross-margin improvement specifically to production and procurement efficiencies and sales mix, not to a fresh sector-wide pricing action. That company-specific explanation should take priority.
Recurring versus exceptional drivers
- Recurring: domestic pharmaceutical demand, product mix, procurement and production efficiency, manufacturing cost, promotional intensity, and local pricing within the regulatory framework.
- Exceptional: the Rs313.2 million SIDC provision reversal and Rs357.2 million present-value remeasurement gain. These should not be treated as a new annual run rate.
- Variable: other income from mutual funds and short-term investments, foreign-exchange movements, and similar treasury items. These can support earnings but are less dependable than pharmaceutical operating profit.
- Early-stage strategic investment: H-Pack Wellness is small but profitable; Hoechst Pack Trading FZCO is pre-revenue and currently dilutive to group profit.
Key risks
The largest near-term operating risk is cost-to-serve. Distribution and marketing expenses are growing much faster than sales, so maintaining gross-margin gains will matter if promotional spending stays elevated. Export concentration is another risk: Afghanistan revenue fell substantially, while the new UAE subsidiary has not yet begun generating sales. Management also flags geopolitical tension in the Middle East, supply-chain disruption, energy-price volatility, inflation and broader macroeconomic pressure. Those risks are particularly relevant for an importer/manufacturer whose margin now benefits from procurement efficiency.
There is also a normalization risk in reported earnings. The SIDC gain is large relative to H1 profit and will not repeat in the same form. A future period can therefore show slower or even negative reported earnings growth despite stable underlying operations. Investors evaluating the next result should compare gross profit and operating profit before unusual other-income items rather than using the H1 2026 PAT growth rate as the baseline.
What to monitor next
The next result cycle should be judged first on whether the roughly 40% gross margin can hold without the help of exceptional income. Watch local sales growth, export recovery, the ratio of distribution and marketing expense to revenue, and whether procurement and production efficiencies continue to offset input and energy pressure. A second check is cash conversion: operating cash flow should ideally catch up with the stronger profit base as the unusually high tax outflow and working-capital timing normalize.
The third monitor is the balance between payouts and expansion. Hoechst has declared another Rs80 per share interim dividend while also funding a new UAE subsidiary and maintaining short-term investment balances. H-Pack Wellness is already profitable but small; Hoechst Pack Trading still needs to prove its commercial model. If the UAE platform begins generating revenue and domestic margins stay strong, the group can broaden its growth base. If it remains pre-revenue while export demand stays weak, it will continue to absorb earnings and management attention.
Overall, H1 2026 was stronger than a one-off-driven result: gross margin expanded, domestic revenue grew, working capital remained controlled and even a simple removal of the disclosed SIDC gain leaves materially higher operating profit. But the quality of the headline 63% PAT growth is not uniform. The next quarter will reveal how much of the current margin improvement is sustainable once the SIDC boost is no longer in the comparison.
Sources
- Hoechst Pakistan Limited — Half Yearly Report 2026, including directors’ reviews, interim financial statements and notes. Open source.
- Pakistan Stock Exchange — HPL company page and official June 30, 2026 result-announcement record. Open source.
- Government of Sindh Law Department — Sindh Development and Maintenance of Infrastructure Cess (Amendment) Act, 2026. Open source.
- Hoechst Pakistan Limited — audited Annual Report 2025, used for historical revenue, margin and profitability context. Open source.
- Drug Regulatory Authority of Pakistan — public pharmaceutical product price index, checked for current regulatory-pricing context. Open source.
- Abbott Laboratories (Pakistan) Limited — official H1/Q2 2026 financial-result announcement, used as a listed-pharma peer cross-check. Open source.